Short description
Palatin Technologies is a biopharmaceutical company developing targeted receptor specific peptide therapeutics to treat diseases.
Description
Palatin Technologies is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for treating diseases with significant unmet medical needs and commercial potential. Their programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Their primary product in clinical development is bremelanotide for treating female sexual dysfunction (FSD). In addition, they have drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, and inflammatory diseases.
Their current focus is on the design and development of receptor-selective melanocortin agonists for inflammation and autoimmune conditions, with a focus on ocular diseases. Their therapeutics work by activating endogenous melanocortin pathways to resolve damaging inflammation and allow affected tissues time to heal. Research has shown melanocortin agonists can prevent and reverse inflammation in disease models, including in the eyes and intestine—two of their targeted areas.
Last funding
Noaccessforu
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Cranbury, New Jersey, United States, North America
Founded on
January 1, 1986
Exited on
October 2, 1997
Went public on
October 2, 1997
Stock symbol
PTN
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noaccessforu, No Way, Noway Youcantaccess, No Way, Noaccess, Cannot Access, Cannot Access, Cannot Access, Nopepepe, Noaccess, Nopepepe
Sign in for full access
Founders
Carl Spana, John Prendergast